EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

11:00am - 12:30pm 90 mins
Cell & Gene Connect
Welcome Remarks and Opening Panel: Evolving landscape of cell and gene therapies
  • Speaker Janet Lambert - CEO, Alliance for Regenerative Medicine
  • Speaker Patricia Reilly - VP, Intelligence Alliances and Product Unification, Pharma intelligence, Informa
12:30pm - 1:30pm 60 mins
Cell & Gene Connect
New partnering models: R&D, hospitals, manufacturers
  • Moderator Morrie Ruffin - Managing Director, Alliance for Regenerative Medicine
  • Speaker Michelle Berg - VP, Patient Affairs and Community Engagement, Abeona Therapeutics
  • Speaker Boro Dropulic - Chief Science Officer and General Manager, Lentigen Technology Inc., A Miltenyi Biotec Company
  • Speaker Walter Kowtoniuk - Advisor, Global Genes; Principal, Third Rock Ventures

In the quickly evolving field of regenerative medicine, it takes collaboration among different stakeholders to bring new therapies to market. How are patient advocacy groups, researchers, hospitals, manufacturers, and others working together to bring promising new research into life-saving treatments? Leaders in this field will share their best practices in partnering with others to reach shared goals.

1:30pm - 2:30pm 60 mins
Cell & Gene Connect
2:30pm - 3:30pm 60 mins
Cell & Gene Connect
Public/private partnerships
  • Speaker Dan Gincel - Executive Director, Maryland Stem Cell Research Fund
  • Speaker Issi Rozen - Chief Business Officer, Broad Institute

With the complex nature of cell and gene therapies, novel collaborations are needed to turn exciting research into viable treatments. How are private research institutions working together with public entities to gain funding and additional resources to facilitate the advancement of new therapies? Learn how successful partnership models can be instrumental in taking research from the lab to the clinic.

3:30pm - 4:30pm 60 mins
Cell & Gene Connect
Commercialization and market access
  • Moderator Amanda Micklus - Principal Analyst, Datamonitor Healthcare

As clinical advances continue to be made and new treatments and potential cures are being developed, how can we ensure that patients will have access to these life changing products? How are new guidelines such as RMAT designation facilitating the approval of new drugs? What types of novel pricing models are being developed to address the high costs of these products? Industry experts will discuss the new paths available for bringing these advanced therapies to market.

4:30pm - 5:00pm 30 mins
Cell & Gene Connect
5:00pm - 6:00pm 60 mins
Cell & Gene Connect
Next generation therapies
  • Speaker Sarah Haecker Meeks - VP, Business Development, Synpromics, Ltd

With exciting progress in the development and commercialization of cell and gene therapies, and CRISPR, CAR-T, and other technologies becoming more mainstream, what are some of the new advances in this field? How are these technologies going to transform healthcare? Are we getting closer to developing cures for diseases instead of treatments for the symptoms?

6:00pm - 8:30pm 150 mins
BioPharm America welcome reception

All BioPharm America attendees are cordially invited to join us.

Showing of Streams
Showing of Streams